Loading...
Docoh

Marinus Pharmaceuticals (MRNS)

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety potential. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 3 trial in refractory status epilepticus, Phase 2 trial in tuberous sclerosis complex and a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy.

MRNS stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Aug 22
26 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 92.33M 92.33M 92.33M 92.33M 92.33M 92.33M
Cash burn (monthly) 11.33M 1.68M 12.26M 8.31M 11.22M 6.47M
Cash used (since last report) 32.83M 4.87M 35.51M 24.09M 32.52M 18.75M
Cash remaining 59.5M 87.46M 56.82M 68.24M 59.81M 73.57M
Runway (months of cash) 5.3 52.0 4.6 8.2 5.3 11.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
24 May 22 Steven Pfanstiel Common Stock Grant Acquire A No No 0 7,448 0 23,998
24 May 22 Joseph Hulihan Common Stock Grant Acquire A No No 0 7,718 0 24,868
24 May 22 Braunstein Scott Common Stock Grant Acquire A No No 0 19,305 0 87,205
24 May 22 Manning Martha E Common Stock Grant Acquire A No No 0 5,790 0 18,657
88.6% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 74 85 -12.9%
Opened positions 16 18 -11.1%
Closed positions 27 11 +145.5%
Increased positions 16 22 -27.3%
Reduced positions 23 25 -8.0%
13F shares Current Prev Q Change
Total value 190.61M 330.44M -42.3%
Total shares 32.97M 34.13M -3.4%
Total puts 112.33K 152.13K -26.2%
Total calls 79.45K 380.45K -79.1%
Total put/call ratio 1.4 0.4 +253.6%
Largest owners Shares Value Change
Lion Point Capital 3.68M $18.96M +1.5%
Suvretta Capital Management 3.51M $16.99M +26.9%
VR Adviser 3.16M $15.28M 0.0%
Avoro Capital Advisors 3.15M $15.25M 0.0%
Venrock Healthcare Capital Partners II 2.88M $34.22M 0.0%
683 Capital Management 1.9M $9.2M -1.7%
Vanguard 1.67M $8.11M -1.3%
Bain Capital Life Sciences Investors 1.43M $6.93M 0.0%
Bleichroeder 1.32M $6.4M 0.0%
Bain Capital Life Sciences Fund 1.3M $15.84M 0.0%
Largest transactions Shares Bought/sold Change
BLK Blackrock 941.31K -1.68M -64.2%
Suvretta Capital Management 3.51M +744.83K +26.9%
STT State Street 130.18K -530.34K -80.3%
Millennium Management 384.07K +384.07K NEW
Geode Capital Management 330.32K -308.9K -48.3%
JPM JPMorgan Chase & Co. 2.07K -290.79K -99.3%
Antara Capital 467.48K +277.27K +145.8%
NTRS Northern Trust 57.08K -261.49K -82.1%
Ergoteles 195.29K +195.29K NEW
Citadel Advisors 219.49K +191.64K +688.1%

Financial report summary

?
Management Discussion
  • We recognized $1.8 million and $3.3 million of federal contract revenue for the three and six months ended June 30, 2022, respectively, as a result of the BARDA Contract. We recognized $1.9 million and $3.7 million for the three and six months ended June 30, 2021, respectively, as a result of the BARDA Contract.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Good
New words: Antitrust, broadened, confirmed, constituting, customary, CV, EFIC, enhance, free, intractable, Nordisk, Novo, Orsini, PK, principle, prodrug, room, sample, waiting, week
Removed: behavioral, composed, conform, consecutive, dependence, distributed, earn, earning, goal, improving, infusion, lack, month, original, recently, reclassified, redeemed, scheduling, sophistication, state, suffering, unresponsive